Compounds > polymyxin b nonapeptide
Page last updated: 2024-11-07

polymyxin b nonapeptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123978
CHEMBL ID501248
SCHEMBL ID21498184
MeSH IDM0116885

Synonyms (7)

Synonym
pmbn
(2s,3r)-2-amino-n-[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1r)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]-3-hydroxybutanamid
CHEMBL501248
86408-36-8
SCHEMBL21498184
HY-106783
CS-0026547
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID476046Toxicity in mouse2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID756416Antibacterial activity against polymyxin-resistant Pseudomonas aeruginosa clinical isolate 1646 assessed as growth inhibition by broth microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID571206Antibacterial activity against Escherichia coli IH3080 assessed as growth inhibition at 10 ug after 18 hrs by CLSI M7-A7 agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID428955Antibacterial activity against LPS-deffective Escherichia coli OC2530 by CLSI broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID571078Antimicrobial activity against methicillin-resistant Staphylococcus aureus OC3726 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1417156Antibacterial activity against Acinetobacter baumannii BAA-1605 after 16 to 18 hrs by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID1579980Potentiation of novobiocin-induced antibacterial activity against wild type Pseudomonas aeruginosa PAO1 assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 512 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID545711Antimicrobial activity against Acinetobacter baumannii ATCC 19606 assessed as zone of inhibition at 10 ug after 18 hrs by disk diffusion method in presence of 1 ug/ml rifampin2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID428956Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID571076Antimicrobial activity against Enterococcus faecium OC3312 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1579989Potentiation of novobiocin-induced antibacterial activity against carbapenem and colistin-resistant Pseudomonas aeruginosa 114228 clinical isolate assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 512 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1580080Induction of outer membrane permeabilization in Pseudomonas aeruginosa PAO1 assessed as increase in accumulation of NPN by measuring fluorescence intensity at 8 ug/ml measured immediately by NPN dye uptake assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1896960Toxicity index, ratio of test compound TC50 to polymyxin B TC50 for cytotoxicity against human differentiated conditionally immortalized RPTEC cells incubated for 24 hrs by PrestoBlue reagent based assay2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.
AID476050Displacement of dansyl-PMB from LPS by isothermal titration calorimetry2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID756410Antibacterial activity against polymyxin-sensitive Escherichia coli isolate 1 assessed as growth inhibition by broth microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID756415Antibacterial activity against polymyxin-sensitive Pseudomonas aeruginosa 1401 assessed as growth inhibition by broth microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID571074Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID571073Antimicrobial activity against Escherichia coli OC9040 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID571072Antimicrobial activity against Escherichia coli OC2605 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID545708Antimicrobial activity against Escherichia coli IH3080 assessed as zone of inhibition at 10 ug after 18 hrs by disk diffusion method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID756417Bactericidal activity against polymyxin-resistant Pseudomonas aeruginosa clinical isolate 16462013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID373177Induction of cell lysis in Pseudoalteromonas ER72M2 assessed as outer membrane permeability at 50 ug/ml2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Polymyxin B induces lysis of marine pseudoalteromonads.
AID1580004Potentiation of novobiocin-induced antibacterial activity against colistin-resistant Enterobacter cloacae 118568 clinical solate assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 1024 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1579985Potentiation of novobiocin-induced antibacterial activity against carbapenem and colistin-resistant Pseudomonas aeruginosa 91433 clinical isolate assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 16 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1896952Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth by CLSI based broth microdilution method2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.
AID1580002Potentiation of novobiocin-induced antibacterial activity against colistin-resistant Klebsiella pneumoniae 113254 clinical isolate assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 256 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1579994Potentiation of novobiocin-induced antibacterial activity against colistin-resistant Acinetobacter baumannii 92247 clinical isolate assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 4 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID1417154Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 18 hrs by CLSI method2018European journal of medicinal chemistry, Sep-05, Volume: 157Synthesis of 1,2,3-triazole linked 4(3H)-Quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus.
AID756413Antibacterial activity against polymyxin-resistant Acinetobacter baumannii clinical isolate 1649 assessed as growth inhibition by broth microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID571075Antimicrobial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID1896953Antibacterial activity against Klebsiella pneumoniae ATCC 13883 assessed as inhibition of bacterial growth by CLSI based broth microdilution method2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.
AID1579992Potentiation of novobiocin-induced antibacterial activity against colistin-resistant Escherichia coli 94393 clinical isolate harboring mcr-1 gene assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 128 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID373174Antimicrobial activity against Pseudoalteromonas ER72M2 up to 50 ug/ml2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Polymyxin B induces lysis of marine pseudoalteromonads.
AID1579987Potentiation of novobiocin-induced antibacterial activity against colistin and carbapenem-resistant Pseudomonas aeruginosa 101243 clinical isolate assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 128 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID571077Antimicrobial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID476056Antimicrobial activity against Escherichia coli assessed as relative sensitizing activity2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Structure--activity relationships of polymyxin antibiotics.
AID545906Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as zone of inhibition at 10 ug after 18 hrs by disk diffusion method in presence of 1 ug/ml rifampin2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID756411Antibacterial activity against polymyxin-sensitive ESBL-positive Klebsiella pneumoniae clinical isolate 3700 assessed as growth inhibition by broth microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID571205Antibacterial activity against Escherichia coli IH3080 assessed as growth inhibition at 10 ug after 18 hrs by CLSI M7-A7 agar dilution method in presence of 1 ug/ml rifampin2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
AID1580095Toxicity in Galleria mellonella larvae MDR Acinetobacter baumannii isolate assessed as larvae protection at 25 mg/kg in combination with novobiocin measured after 24 to 96 hrs relative to control2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID428967Antibacterial activity against Escherichia coli NovaBlue by CLSI broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli.
AID545709Antimicrobial activity against Escherichia coli IH3080 assessed as zone of inhibition at 10 ug after 18 hrs by disk diffusion method in presence of 1 ug/ml rifampin2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1580097Potentiation of novobiocin-induced antibacterial activity against novobiocin and colistin resistant Acinetobacter baumannii ATCC 17978 mutant generated from seven serial passages by checkerboard assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID756414Bactericidal activity against polymyxin-resistant Acinetobacter baumannii clinical isolate 16492013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID545710Antimicrobial activity against Acinetobacter baumannii ATCC 19606 assessed as zone of inhibition at 10 ug after 18 hrs by disk diffusion method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1896955Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth by CLSI based broth microdilution method2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.
AID1579998Potentiation of novobiocin-induced antibacterial activity against colistin-resistant Escherichia coli 94474 clinical isolate harboring mcr-1 gene assessed as novobiocin MIC at <= 7.1 uM incubated for 18 hrs by CLSI protocol based assay (Rvb = 256 ug/ml)2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent against Gram-Negative Bacteria.
AID571071Antimicrobial activity against LPS-deffective Escherichia coli OC2530 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID571080Antimicrobial activity against Staphylococcus aureus OC4172 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID545712Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as zone of inhibition at 10 ug after 18 hrs by disk diffusion method2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
AID1896954Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as inhibition of bacterial growth by CLSI based broth microdilution method2022Journal of medicinal chemistry, 12-08, Volume: 65, Issue:23
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.
AID756409Cytotoxicity against human RPTEC after 24 hrs by LDH assay2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID571079Antimicrobial activity against methicillin-resistant Staphylococcus aureus OC2878 by broth microdilution method2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
MurF inhibitors with antibacterial activity: effect on muropeptide levels.
AID756412Antibacterial activity against polymyxin-sensitive Acinetobacter baumannii clinical isolate 3167 assessed as growth inhibition by broth microdilution method2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
AID1194559Effect on outer membrane permeability in AcrAB-deficient Escherichia coli HN1159 assessed as influx of nitrocefin at 20 ug/ml2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.
AID373175Induction of cell lysis in Pseudoalteromonas ER72M2 assessed as cytoplasmic membrane integrity at 50 ug/ml2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Polymyxin B induces lysis of marine pseudoalteromonads.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's6 (54.55)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.70 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		2.1110hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.2110aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.1710carbohydrazideantitubercular agent;
drug allergen
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.2110C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		2.0310ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		2.44204-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.0410cyclic ketone;
erythromycin
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.7730glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
tobramycin
Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.		2.2110amino cyclitol glycosideantibacterial agent;
antimicrobial agent;
toxin
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.1110penicillin allergen;
penicillin		antibacterial drug
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.4520macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.54209-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.4920alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.4520alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		2.4520macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
fusidic acid
Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.		2.452011alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester		EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor
ceftazidime
[no description available]		2.2110cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
gentamicin sulfate
[no description available]		2.0410
polymyxin b(1)
[no description available]		2.0810
polymyxin b2
[no description available]		3.1510polymyxin
nab741
SPR741: a novel agent with structural similarity to polymyxins that is capable of potentiating the activities of various classes of antibiotics		2.0510
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		2.2110carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		2.2110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.0140cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Infections, Gram-Negative
[description not available]		02.9710
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		02.9710
Health Care Associated Infection
[description not available]		02.0810
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.0810
Infections, Staphylococcal
[description not available]		02.1710
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.1710